A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. rFVIIa Study Group.
about
Bypassing agent prophylaxis in people with hemophilia A or B with inhibitorsRecombinant factor VIIa concentrate versus plasma-derived concentrates for treating acute bleeding episodes in people with haemophilia and inhibitorsRecombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophiliaRecombinant Factor VIIa concentrate versus plasma derived concentrates for the treatment of acute bleeding episodes in people with haemophilia and inhibitorsRecombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophiliaRecombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophiliaRecombinant Factor VIIa concentrate versus plasma derived concentrates for the treatment of acute bleeding episodes in people with Haemophilia A and inhibitorsThe Australian and New Zealand Haemostasis Registry: ten years of data on off-licence use of recombinant activated factor VII.Safety and efficacy of recombinant factor VIIa by pediatric age cohort: reassessment of compassionate use and trial data supporting US label.Transfusion medicine service policies for recombinant factor VIIa administration.Recombinant factor VIIa.Recombinant factor VIIa versus aPCCs in haemophiliacs with inhibitors: treatment and cost considerations.Recombinant activated factor VII in controlling bleeding in non-hemophiliac patientsPerinatal management of newborns with haemophilia.New-generation recombinant factor concentrates: bridge to gene therapy.Potential role for rFVIIa in transfusion medicine.Current difficulties and recent advances in bypass therapy for the management of hemophilia with inhibitors: a new and practical formulation of recombinant factor VIIa.Gene therapy ethics and haemophilia: an inevitable therapeutic future?Control of bleeding in patients with haemophilia A with inhibitors: a systematic review.Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors.Recombinant Factor VIIa: clinical applications for an intravenous hemostatic agent with broad-spectrum potential.Recombinant Factor VIIa in Post-partum Hemorrhage: A New Weapon in Obstetrician's Armamentarium.Treatment of factor XI inhibitor using recombinant activated factor VIIa.Recombinant factor VIIa in the treatment of non-hemophiliac bleeding.Recombinant activated factor VII and the anaesthetist.The emerging role of recombinant activated Factor VII (rFVIIa) in the treatment of blunt traumatic haemorrhage.A critical appraisal of the use of recombinant factor VIIa in acquired bleeding conditions.The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation.Recombinant factor VIIa in paediatric bleeding disorders--a 2006 review.An overview of the history, clinical practice concerns, comparative studies and strategies to optimize therapy of bypassing agents.Recombinant activated clotting factor VII (rFVIIa) in the treatment of surgical and spontaneous bleeding episodes in hemophilic patientsHealth economic review of recombinant activated factor VII for treatment of bleeding episodes in hemophilia patients with inhibitors.Barriers and perceived limitations to early treatment of hemophilia.Inhibitor development in haemophilia B: an orphan disease in need of attention.Recombinant activated factor VII in post partum haemorrhage.Enhancement of the efficacy of therapeutic proteins by formulation with PEGylated liposomes; a case of FVIII, FVIIa and G-CSF.Evidence supporting the use of recombinant activated factor VII in congenital bleeding disorders.Optimal use of recombinant factor VIIa in the control of bleeding episodes in hemophilic patients.The use of PEGylated liposomes in the development of drug delivery applications for the treatment of hemophilia.Reversal of antithrombotic agents.
P2860
Q24187021-17411DE3-889A-496E-AFB5-826F7CC3BF5EQ24187069-A47BA279-3BE8-4A6E-825E-D69D29CE35F6Q24201292-6938DA7B-7956-49B2-A272-D0E08B12B52DQ24236388-12989A3E-2A36-46D6-881A-EA607EA9D983Q24236583-2EA5D194-EC3B-4495-BB1F-857379457DEAQ24245204-013F9689-71EB-4AB4-B39F-E29E6EE67868Q24247217-50ECC510-C7B7-481F-A23C-AC5F77B8EC51Q30833127-EEA9BF7B-0782-423D-A10F-541284E10332Q31102998-BFB3CCCF-B269-466D-B506-17ADF986E30FQ33362187-42F9846E-76E0-4674-9A83-1336305AF290Q33363658-47FDE64D-C59E-4F86-9BAB-568A69C3954BQ33794101-078AB74D-B97C-412E-8E99-D3C913246393Q33918017-885594B0-4780-4EBD-819B-7699EF5938F1Q34135323-799B2BD0-C873-413E-B5E0-2B08A8F3BFCDQ34176033-BEAF300C-39CC-4D34-ADEE-B36BA60F6766Q34564930-65BDDB2D-F2D0-47BD-8E26-0738FA44A839Q34999749-1A5DF3BD-16F5-4D84-AB72-980DBC5793F6Q35076713-4C0D077B-6C39-49C2-AAE3-71B7AAA933C6Q35163644-3411CEF9-695F-4CC2-B6C4-7376BD132CE5Q35771690-30A3FDEC-510E-4146-80DD-EAA585149A47Q35879063-E1811B05-A529-4F26-A13A-1A1C54EC91BEQ35906504-1B804CE4-B69D-414A-8417-F1DD59C0E66EQ36014991-877E2EE3-1B33-42A9-AFAC-0B1346B96698Q36077574-F8648F34-73AB-47EF-A255-808DE5844659Q36313315-4054BBD4-AB45-4F51-8374-F03483D8F9B5Q36349573-C0C4DA02-F822-471E-9685-444CA6082877Q36462093-708AB6D0-F979-41BB-ACA5-F23A1C5412D4Q36480548-31A7FB4D-5790-486F-80B9-DBEF3F874BD9Q36570888-451F415D-6115-4C0D-BB1A-DBB9351A8E8BQ36661836-98B41DCE-A070-4FEA-9922-ED3DD25C9411Q36745575-D76C3B5A-A266-4C18-92EE-2E0E6A92DA25Q36828144-301A37B1-0B22-4375-9EB2-E3FDF0BAD618Q36863077-427485F3-A7E5-41DB-B6ED-22D54DF886A5Q36872038-0191A2A2-753D-4B56-A08D-2FFFC89342F7Q37443253-FF4C2EB3-D4A3-4560-A749-F4BF913827F5Q37679949-A3539090-13D1-4B4B-B8AF-4CB071F64092Q37778291-2A35EAB5-634B-4AA9-AAB9-61638B40C421Q37778292-9C68AD92-3854-4F74-91DF-FBE2E187A8DCQ37790614-69E1EA85-7133-4DBF-9D1B-00DCD0ED3434Q37998377-B1D39792-3E4D-4B1C-8481-4F3413086BCD
P2860
A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. rFVIIa Study Group.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh-hant
name
A randomized, double-blind com ...... nhibitors. rFVIIa Study Group.
@en
A randomized, double-blind com ...... nhibitors. rFVIIa Study Group.
@nl
type
label
A randomized, double-blind com ...... nhibitors. rFVIIa Study Group.
@en
A randomized, double-blind com ...... nhibitors. rFVIIa Study Group.
@nl
prefLabel
A randomized, double-blind com ...... nhibitors. rFVIIa Study Group.
@en
A randomized, double-blind com ...... nhibitors. rFVIIa Study Group.
@nl
P2093
P2860
P921
P1433
P1476
A randomized, double-blind com ...... nhibitors. rFVIIa Study Group.
@en
P2093
Davignon G
Mannucci PM
Roberts HR
P2860
P304
P356
10.1046/J.1365-2516.1998.00209.X
P577
1998-11-01T00:00:00Z